131I-MIBG WITH INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究中的治疗方法包括获得一种具有放射性的新药。这种放射性药物(131I-MIBG)是为了希望IF能导致癌细胞死亡。在给予这种药物后，受试者将接受三种化疗药物，然后用受试者自己的细胞进行干细胞移植。这是一项第二阶段的试验，旨在了解这种治疗是否能清除癌细胞，以及这种治疗可能会导致什么副作用。我们不知道这种疗法是否有效。全部用放射药物治疗，化疗，干细胞移植，恢复时间，将需要6个月左右。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The therapy in this study involves getting a new drug that is radioactive. The radioactive drug (131I-MIBG) is given in hopes that if will cause the cancer cells to die. After this drug is given, the subject will receive three chemotherapy drugs followed by a stem cell transplant with the subject's own cells. This is a Phase II trial looking to see if this treatment gets rid of the cancer cells and what side effects this treatment may cause. We do not know if this therapy will be effective. The total treatment with the radioactive medicine, chemotherapy, stem cell transplant, and recovery time, will take about 6 months.